Drug Trial Radar · NCT05561751
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Feb 13, 2023
Primary completion
Sep 30, 2025
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- GPCR Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arms: * GPC-100 in combination with propranolol; or * GPC-100 in combination with propranolol and G-CSF. To characterize the safety and clinical activity of GPC-100, the study will employ a Bayesian Optimal Phase II (BOP2) design to enroll patients for each arm. All patients will receive via IV 3.14 mg/kg GPC-100 (Burixafor) at least 2 hours prior to leukapheresis sessions from Days 7-8 (Days 9-11 optional) and 30 mg propranolol (3 x 10 mg tablets) twice daily at 8:30 AM (+/- 1 hr) and 4:00 PM (+/- 1 hr) local time from Days 1 to 8 (and on Days 9-11, if applicable). Patients will administer the first dose of propranolol onsite on Day 1. Patients will be provided with doses of propranolol for self-administration at time points when they are not otherwise required to be onsite. Sites should contact patients via telephone to confirm propranolol administration for doses administered outside of clinic.
Conditions
- Multiple Myeloma
Interventions
GPC-100Drug
GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min
PropranololDrug
propranolol
G-CSFDrug
G-CSF
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants That Achieve >=2 x 10^6 CD34+ Cells/kg in 2 Leukapheresis SessionsTime frame: First two leukapheresis sessions (study days 7 and 8)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Diego (UCSD) - Moores Cancer Center
La Jolla, California
University of Florida (UF) - Shands Cancer Center
Gainesville, Florida
Indiana Blood and Marrow Transplantation
Indianapolis, Indiana
University of Massachusetts
Worcester, Massachusetts
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
John Theurer Cancer Center At Hackensack UMC
Hackensack, New Jersey
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York
The Cleveland Clinic Foundation
Cleveland, Ohio
MD Anderson Cancer Center
Houston, Texas
Virginia Commonwealth University - Massey Cancer Center
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.